Man Who Predicted COVID 19 Crash Warns of New Crisis

Analyst Targets

• Morgan Stanley: Buy, CHF 135 price target (maintained post-data)
• Deutsche Bank: Buy rating (reaffirmed September 2, 2026)
• Barclays: Hold (maintained September 1, 2026)
• Analyst consensus: Moderate Buy, consensus target CHF 127.73 (Swiss francs)

What Happened

Novartis shares climbed after the Swiss drugmaker announced positive results from two late-stage trials of its oral MS drug remibrutinib, with the stock gaining 4.5% by European midday on September 1, pushing its year-to-date advance to 18%.

The two Phase 3 studies, REMODEL-1 and REMODEL-2, each enrolled approximately 1,000 patients with relapsing multiple sclerosis and compared remibrutinib against teriflunomide, sold by Sanofi under the brand name Aubagio. Both met their primary endpoint. Both showed superiority on every prespecified secondary measure, including MRI lesion reduction. The disability data landed cleanly too: in a preplanned combined analysis of the two trials, remibrutinib showed a positive trend in 3-month confirmed disability progression and reached nominal significance for 6-month confirmed disability progression versus teriflunomide.

The Number That Changes Everything

The company reported a favorable safety profile with no liver safety signal and no cases meeting Hy’s Law criteria, consistent with the broader remibrutinib program spanning more than 4,500 participants across neurologic and immune-mediated indications. That single sentence may matter more than any efficacy figure in the readout.

The BTK class has been defined as much by its failures as its promise. The FDA previously focused on Sanofi’s tolebrutinib for a serious risk of drug-induced liver injury. Roche’s fenebrutinib has also faced questions over its safety profile, dampening expectations for its eventual approval. Remibrutinib’s liver-clean readout across roughly 2,000 REMODEL patients, plus the broader 4,500-patient dataset, is not a footnote. It is the differentiator.

Sizing the Opportunity

Analysts say remibrutinib could generate as much as $9 billion in peak annual sales across all indications if development is successful. Investors are focused on remibrutinib, heart drug pelacarsen, and gene therapy del-desiran, which together are seen generating more than $10 billion in peak annual sales and underpinning the company’s long-term growth.

Peak-sales estimates of that magnitude raise a familiar question for biotech investors: does the current share price already discount the upside, or is the market still catching up to what the drug is becoming? It is the same valuation puzzle playing out elsewhere in large-cap pharma right now. our analysis of whether Gilead’s multiple reflects lenacapavir’s expanding platform value walks through a framework for thinking about exactly that kind of repricing — one that applies equally well to a drug like remibrutinib that is still early in its commercial story.

The MS indication is the largest piece of that. Relapsing-remitting MS represents 63.5% of the MS application segment in 2026, supported by the highest diagnosed patient volumes and broadest range of approved therapies. Monoclonal antibodies account for 41.6% of the product segment, led by B-cell depleting agents including ocrelizumab and ofatumumab. Those infused and subcutaneous anti-CD20 agents are the actual competitive target, not teriflunomide. Beating Aubagio proves clinical superiority; displacing Ocrevus and Kesimpta is where the revenue sits.

The oral route is remibrutinib’s weapon. Remibrutinib blocks B-cell receptor and Fc receptor signaling, limiting activation of B cells and innate immune cells implicated in MS-related neuroinflammation, which is the same pathological ground anti-CD20 drugs occupy. An oral drug matching that mechanism of action, with demonstrated liver safety, gives neurologists and patients a genuine alternative to infusion chairs and injection devices.

Bull / Base / Bear

Bull: Global filings proceed without delay. Full data presented at MSToronto2026 in October show ARR reductions competitive with anti-CD20 class benchmarks. Label covers broad relapsing MS, remibrutinib captures meaningful share of new high-efficacy starts, and the REMASTER trial in secondary progressive MS adds a second population. Peak sales approach the $9 billion analyst ceiling across indications.

Base: Approval secured in major markets through 2028. Remibrutinib establishes itself as the leading oral high-efficacy option, taking share at the margin from infused agents among patients prioritizing convenience. Patent losses on Entresto weigh on near-term growth, but a strong portfolio of newly launched drugs and the remibrutinib ramp ensure a steady long-term outlook. Peak sales land in the $5 to $7 billion range across all indications.

Bear: Full data at MSToronto reveal ARR reductions below anti-CD20 class thresholds, giving payers and neurologists reason to keep established agents first-line. Any unexpected signal in the open-label extension disrupts the regulatory path.

Technical Overlay

NVS gapped higher on September 1, adding 4.5% on elevated volume. The 52-week range runs from $121.57 to $170.46, with the all-time closing high of $163.64 posted on February 27, 2026. The stock now trades near the middle of that band. Gap support at the pre-announcement level provides near-term downside reference; the February highs represent the next meaningful resistance zone for fresh buyers.

Bottom Line

The REMODEL data resolve the question that mattered most: can a BTK inhibitor in MS avoid the liver toxicity that grounded its predecessors? For remibrutinib, the answer across more than 4,500 patients is yes. UBS analyst Matt Weston wrote that remibrutinib looks like it is at least a best-in-class oral agent. The debate now shifts from whether the drug works to how aggressively it can take share from anti-CD20 standards that require hospital infusions or weekly injections. Full efficacy numbers at MSToronto2026 in October will set that argument in concrete.